Wright Medical Technology, Inc. is an orthopedic medical-device maker headquartered at 5677 Airline Rd, Arlington, Tennessee. The business traces to Wright Manufacturing, founded in 1950; it was renamed Wright Medical Technology in 1993 after a private-equity buyout, went public in 2001 (Nasdaq: WMGI), and later became a subsidiary of Wright Medical Group N.V., an Amsterdam-domiciled holding company created by the 2015 combination with Tornier N.V. Stryker Corporation acquired Wright Medical Group in a November 2020 deal valued at roughly $4 billion equity / $5.4 billion enterprise value. Wright Medical Technology now operates as a Stryker subsidiary. Press reports at the time put global employment above 3,000 with sales approaching $1 billion.
Products / operations. Wright designs and manufactures joint implants and instrumentation, organized into four lines: upper extremities (shoulder, elbow, wrist, hand — e.g., AEQUALIS and SIMPLICITI shoulder systems, EVOLVE radial head), lower extremities (foot and ankle — INBONE, INFINITY and INVISION total ankle replacement systems, ORTHOLOC and DARCO plating, hammertoe systems), biologics (AUGMENT Bone Graft based on rhPDGF-BB, GRAFTJACKET, ALLOMATRIX, OSTEOSET, PRO-DENSE), and sports medicine/other. It also sells patient-specific preoperative planning tools such as the PROPHECY navigation guides and BLUEPRINT 3D shoulder planning software.
Litigation posture. This is an operating company, not an assertion entity. In the tracked data it appears once, solely as a defendant (zero plaintiff cases). The single case is Conformis, Inc. v. Wright Medical Technology, Inc. et al., filed 2020-04-24 in the U.S. District Court for the District of Delaware — a venue Conformis also used against other orthopedic manufacturers, not the Eastern District of Texas.
Case context. Conformis alleged that Wright's patient-specific shoulder instruments — and the implant components used with them — infringed Conformis patents covering personalized implants and patient-specific instrumentation. The dispute settled in July 2021, after Stryker's acquisition closed; under the settlement Stryker made a one-time payment reportedly about $15 million and received a non-exclusive license to certain Conformis patents.